0 Commenti
0 condivisioni
228 Views
0 Anteprima
Cerca
Scopri nuove persone e i loro amici a quattro zampe, e fai nuove amicizie
-
Effettua l'accesso per mettere mi piace, condividere e commentare!
-
Biosimilar Market Size, Share, Trends, Key Drivers, Demand and Opportunity Analysis"Regional Overview of Executive Summary Biosimilar Market by Size and Share The global biosimilar market size was valued at USD 64.93 billion in 2024 and is expected to reach USD 598.55 billion by 2032, at a CAGR of 32.00% during the forecast periodThe market expansion is primarily driven by the growing number of patent expiries of blockbuster biologics and the rising prevalence of...0 Commenti 0 condivisioni 979 Views 0 Anteprima
-
Biosimilars Market Forecast and Industry Outlook Through 2028The biosimilars market is expected to continue expanding rapidly due to ongoing advancements in biotechnology and supportive regulatory frameworks. Increasing demand for affordable biologic therapies will remain a key driver. These factors indicate strong future growth for the global biosimilars industry. The global Biosimilars Market is experiencing remarkable growth as healthcare systems...0 Commenti 0 condivisioni 4K Views 0 Anteprima
-
Global Biosimilars Market Growth Driven by Rising Biologic DemandThe Biosimilars Market is experiencing rapid growth due to the increasing demand for cost-effective alternatives to biologic drugs. Healthcare systems across the world are adopting biosimilars to reduce treatment costs while maintaining similar therapeutic effectiveness. This growing acceptance is significantly supporting the expansion of the biosimilars industry. The global Biosimilars Market...0 Commenti 0 condivisioni 3K Views 0 Anteprima
-
Global Recombinant Human Insulin Market to Reach USD 9.7 Billion by 2034 Amid Rising Diabetes BurdenAccording to a new report from Intel Market Research, the global Recombinant Human Insulin market was valued at USD 5.8 billion in 2025 and is projected to reach USD 9.7 billion by 2034, growing at a CAGR of 5.6% during the forecast period (2026–2034). This sustained growth reflects the increasing global burden of diabetes and the shift toward biotechnology-derived insulin therapies that...0 Commenti 0 condivisioni 2K Views 0 Anteprima